ANZCTR search results

This pilot program aims to boost wellbeing and engagement among people aged 65 years and older. It supports participants to plan and do personally meaningful and enjoyable activities to lead a more rewarding life. This behavioural activation approach has been demonstrated to help people become happier in studies around the world and is also a very effective treatment for depression. Our goal in this pilot is to test whether a tailored version of this well established wellbeing intervention increases engagement, valued activity, health, and wellbeing in an older adult population.

Forty healthy adult subjects will be recruited to attend three data collection sessions at the CASS labs at Deakin University Burwood Campus. During any session, participants will be provided with any one mouth rinse in a random order: containing fatty acid (oleic acid 20mM), containing triglyceride (vegetable oil isocaloric to the fatty acid wash; positive control), or containing neither (negative control). They will then return to the lab after 90 minutes for an ad libitum buffet lunch, where they will be able to consume as much or as little food as they like. Food intake will be measured to assess the effect of the mouth rinse on intake. Participants will return to the CASS lab on separate days to complete the same methods, but with the other two remaining mouth rinses (cross-over design). Data will be collected via the researcher weighing food and plates to calculate the exact quantity of food intake. This will be performed in a separate room to the buffet to ensure there is no influence on the participants. Additional measures: • Participants will keep a food record of their intake on the morning of each session. This will be completed using an online tool – ASA24 Australia • Participants will complete satiety questionnaires before and after lunch to ensure they are comfortably full following buffet. These will be completed using an online survey software – Compusense Cloud The aim is to assess the effects of a fatty acid-based mouth rinse on acute appetite and ad libitum food intake. We hypothesise that the fatty acid-based mouth rinse will reduce food intake compared to a control rinse.

The purpose of the study is to assess the efficacy of the i-CBT stress and well-being program for university students. We expect that the participants in the treatment group will show lower levels of psychological distress and higher levels of well-being at post-treatment and one-month follow up than participants in the waitlist control group.

The RECARDINA project will evaluate two possible approaches to an innovative screening protocol for congenital and rheumatic heart disease (RHD) in school-aged children and young people, using briefly-trained healthcare workers conducting handheld, single view (SPLASH) echocardiography. Both approaches could potentially be scaled up to allow for screening very large numbers of children in a short period of time. The first approach is a screen and refer approach, whereby briefly-trained healthcare workers identify suspected abnormal scans, and refer these children on for further evaluation by a cardiologist; the second approach involves offsite expert review of all echo images obtained by the briefly-trained healthcare workers to identify which children have heart disease and require further follow up or treatment. The two approaches to screening will be evaluated in terms of diagnostic accuracy and which produces the highest yield of significant heart disease cases, in settings with limited resources and a high burden of undetected RHD. The Recardina study will take place in urban and rural sites in Timor-Leste and the Northern Territory.

The D4D/D4T2DM trial is designed as a multi-centre, single-blind, randomized, parallel group, superiority study to determine the role of Vitamin D from the oral supplement, sun exposure and dietary invention in controlling and reducing DM risks. The current study hypothesised that adequate vitamin D level will help with correcting blood sugar level and HbA1c. Eligible participants will be randomised in equal proportion into one of 4 groups: vitamin D supplement, dietary intervention, sun exposure and control group for duration of 9 months. This study will help to understand and explain the possible association between vitamin D and Diabetes Mellitus, help to reduce the cost of clinical care; the cost of medicine; reduce the compliance of DM and reduce the incidence of hospitalization.

The purpose of this study is to assess the safety, tolerability of the drug INCB099318 and assess how this drug acts in the body with and without food in increasing doses. You may be eligible for this study if you are a male or female, aged 18 to 55, and you are in good health with no existing conditions. Participants in this study will be randomized (by chance) in each of the 6 cohort. In Cohorts 1-5 all participants will either receive a single dose of the drug or placebo (orally in a fasted condition (no food). In Cohort 6 subjects will be randomly assigned to treatment A or treatment B groups. Subjects in treatment A group will be dosed after fasting for 8 hrs. Subjects in treatment B group will be fed a high-fat calorie meal before 30 min of dose administration. All cohort 6 participants will receive two single doses of drug. Participants will also provide blood and urine samples. It is hoped this research will provide information as to how this drug acts in the body in fed and fasted conditions, results from the study will affect how patients with cancer use this medication.

Studies have consistently shown that ketamine and dexmedetomidine infusions on their own provide good and safe analgesia, decrease opioid requirements and can increase the pain-free period during the postoperative recovery. A combination of dexmedetomidine and ketamine may prevent adverse events associated with Ketamine use such as tachycardia, hypertension, salivation, as well as reduce anxiety from ketamine, whereas ketamine may prevent the bradycardia and hypotension, which has been reported with dexmedetomidine. What is more, IN is an attractive needle-free sedative option where IV access is unnecessary or may be deferred until sedation is achieved. Both ketamine and dexmedetomidine are efficacious and well tolerated when provided as an IN preparation. To our knowledge, however, very few studies have examined a combined formulation. This study will therefore seek evaluate the sedative, anxiolytic, and analgesic effects of combined dexmedetomidine and ketamine when administered via the nasal route in healthy adults.

Cerebral palsy (CP) is the commonest physical disability in childhood. Respiratory illness is the leading cause of death for children with CP, and is responsible for more multi-day hospital admissions than any other cause. Children with CP admitted to hospital for respiratory illness stay in hospital, on average, 2.5 times longer than other children, and two in five are re-admitted the following year. At present, there is no coordinated approach to preventing respiratory illness in children with CP. Children with respiratory illness are usually not referred for specialized care until their respiratory illness is advanced and often life-threatening. The BREATHE-CP (Better REspiratory and Airway Treatment and HEalth in Cerebral Palsy) research team have determined the early risk factors for respiratory illness in children with CP so that they can be treated much earlier. We have also systematically reviewed the research literature to determine the most effective treatments for preventing respiratory disease. However, there is very little research evidence. Treatment studies are urgently needed. We have also asked researchers and clinicians worldwide with expertise in respiratory health in CP what treatment approaches they would recommend, and developed a consensus statement for management of respiratory illness in children with CP. This study will trial this recommended approach to management of respiratory illness in children with CP. Treatments will be individualized for children with CP at risk of respiratory illness to find out whether they are feasible, acceptable, and likely to be effective by comparison with current standard treatment. If the trial is successful, we will apply for funding to do a large-scale trial across several hospitals to improve respiratory health and quality of life for children with CP at risk of respiratory illness and reduce healthcare costs.

Substantial evidence tells us that people with intellectual disability (ID) urgently need accessible and affordable mental healthcare options. Despite electronic mental health (eMH) making mental health more affordable and accessible, Australians with ID cannot access the eMH programs that their peers now take for granted. A specifically designed eMH tool has the potential to close this gap and place crucial mental health services in the hands of thousands of Australians with borderline-to-mild ID. To our knowledge, our purpose-designed eMH health tool (named Healthy Mind) is the first program of its kind designed by and for people with ID. Healthy Mind is the product of considerable research, clinical and life expertise gathered across many individuals and organisations. Our tool is designed to target the most commonly experienced symptoms of psychological distress in people with ID. It is based on empirically effective strategies that have been demonstrated to improve anxiety and depression in previous trials involving people with ID. This project aims to establish if Healthy Mind can help Australians (16yo and over) with borderline-to-mild ID reduce symptoms of anxiety and depression and improve their day-to-day functioning. A secondary aim of this project is to determine if Healthy Mind can help support the mental health of younger Australians with borderline-to-mild ID as they experience a stressful life transition, such as moving into a more independent living arrangement or commencing employment. We hope that individuals who use Healthy Mind will experience reduced anxiety and depression, and increased daily functioning, when compared with individuals in a control group. We also hope that individuals who use Healthy Mind while undertaking a stressful life transition will report better coping and lower stress in response to their life transition than similar individuals in a control condition. The potential benefits of a program like Healthy Mind are wide-ranging. With improved access to mental healthcare, people with ID and their families will likely require fewer support services, experience fewer carer days-out-of-role and increased levels of community participation, including greater employment. Additionally, the specialised nature of Healthy Mind appears to help users feel empowered and included. Initial user testing has revealed not only the feasibility and acceptability of Healthy Mind, but also excitement and gratitude for an eMH program designed by and for people with ID.

Midline Catheters (MCs) and Peripherally Inserted Central Catheters (PICCs) are devices which are inserted peripherally into a vein in the upper arm under ultrasound guidance. These are used to deliver medical treatment, including medicines, fluids, and blood transfusions. The main difference between these two devices is the length of the catheter, and where the tip of the device ends (MC, near the shoulder; PICC, centrally). This randomised controlled trial involves being randomly allocated to one of two arms: • Insertion of a Peripherally Inserted Central Catheter (50-55cms) • Insertion of a Midline Catheter (8-20cms) The aim of the trial is to compare MC with PICC for patients requiring prolonged intravenous therapy (up to or equal to 29 days). The researchers hypothesise there will be no significant difference for all-cause device failure between patients who receive a MC versus a PICC.